T cell engineering as therapy for cancer and HIV: Our synthetic future

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1680, 2015, Pages

  June, Carl H ^a,b   Levine, Bruce L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Immunotherapy; Synthetic biology

Indexed keywords

BIOLOGY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; GENETIC ENGINEERING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM;

HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; CELL ENGINEERING; GENETIC ENGINEERING; GENETICS; HIV INFECTIONS; HUMAN; IMMUNOLOGY; NEOPLASMS; PROCEDURES; SYNTHETIC BIOLOGY; T LYMPHOCYTE; TRENDS; TUMOR ASSOCIATED LEUKOCYTE;

CELL ENGINEERING; GENETIC ENGINEERING; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SYNTHETIC BIOLOGY; T-LYMPHOCYTES;

EID: 84942930968     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0374     Document Type: Review

References (78)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998. (doi:10.1038/ni1102-991)
2. Rosenberg SA, Yang JC, Restifo NP. 2004 Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915. (doi:10.1038/nm1100)
3. Billingham RE, Brent L, Medawar PB. 1954 Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc. R. Soc. Lond. B 143, 58–80. (doi:10.1098/rspb.1954.0054)
4. Mitchison NA. 1955 Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102, 157–177. (doi:10.1084/jem.102.2.157)
5. Chen YY, Galloway KE, Smolke CD. 2012 Synthetic biology: advancing biological frontiers by building synthetic systems. Genome Biol. 13, 240. (doi:10.1186/gb-2012-13-2-240)
6. Gross G, Waks T, Eshhar Z. 1989 Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024–10028. (doi:10.1073/pnas.86.24.10024)
7. Irving BA, Weiss A. 1991 The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–901. (doi:10.1016/0092-8674(91)90314-O)
8. Mellman I, Coukos G, Dranoff G. 2011 Cancer immunotherapy comes of age. Nature 480, 480–489. (doi:10.1038/nature10673)
9. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang K-M, Jakobsen BK. 2012 Different affinity windows for virus and cancerspecific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174–3179. (doi:10.1002/eji.201242606)
10. Ghazi A et al. 2012 Generation of polyclonal CMVspecific T cells for the adoptive immunotherapy of glioblastoma. J. Immunother. 35, 159–168. (doi:10.1097/CJI.0b013e318247642f)
11. Sampson JH, Mitchell DA. 2011 Is cytomegalovirus a therapeutic target in glioblastoma? Clin. Cancer Res. 17, 4619–4621. (doi:10.1158/1078-0432.CCR-11-0992)
12. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. 2012 Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirusspecific T-cells in patients with glioblastoma multiforme. Immunol. Cell Biol. 90, 872–880. (doi:10.1038/icb.2012.19)
13. Tebas P et al. 2014 Gene editing of CCR5 in autologous CD4 T-cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910. (doi:10.1056/NEJMoa1300662)
14. Hinrichs CS, Rosenberg SA. 2014 Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257, 56–71. (doi:10.1111/imr.12132)
15. Dudley ME et al. 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233–5239. (doi:10.1200/JCO.2008.16.5449)
16. Linnemann C, Mezzadra R, Schumacher TN. 2014 TCR repertoires of intratumoral T-cell subsets. Immunol. Rev. 257, 72–82. (doi:10.1111/imr.12140)
17. Andersen RS et al. 2012 Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650. (doi:10.1158/0008-5472.CAN-11-2614)
18. Robbins PF et al. 2013 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752. (doi:10.1038/nm.3161)
19. Castle JC et al. 2012 Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091. (doi:10.1158/0008-5472.CAN-11-3722)
20. Matsushita H et al. 2012 Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404. (doi:10.1038/nature10755)
21. Sadelain M, Brentjens R, Riviere I. 2013 The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398. (doi:10.1158/2159-8290.CD-12-0548)
22. Chmielewski M, Hombach AA, Abken H. 2014 Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257, 83–90. (doi:10.1111/imr.12125)
23. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. 2014 CAR T cells: driving the road from the laboratory to the clinic. Immunol. Rev. 257, 91–106. (doi:10.1111/imr.12126)
24. Ruella M, Kalos M. 2014 Adoptive immunotherapy for cancer. Immunol. Rev. 257, 14–38. (doi:10.1111/imr.12136)
25. Jensen MC, Riddell SR. 2014 Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257, 127–144. (doi:10.1111/imr.12139)
26. Lamers C et al. 2011 Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells. Blood 117, 72–82. (doi:10.1182/blood-2010-07-294520)
27. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. 2013 T Cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31. (doi:10.1158/2326-6066.CIR-13-0006)
28. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. 2012 Tumortargeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141. (doi:10.1182/blood-2011-12-400044)
29. Teachey DT et al. 2013 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 121, 5154–5157. (doi:10.1182/blood-2013-02-485623)
30. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. 2014 How I treat: current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195. (doi:10.1182/blood-2014-05-552729)
31. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. 1999 Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507–513.
32. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. 2000 Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74, 8207–8212. (doi:10.1128/JVI.74.17.8207-8212.2000)
33. Li Y et al. 2005 Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349–354. (doi:10.1038/nbt1070)
34. Chervin AS, Aggen DH, Raseman JM, Kranz DM. 2008 Engineering higher affinity T cell receptors using a T cell display system. J. Immunol. Methods. 339, 175–184. (doi:10.1016/j.jim.2008.09.016)
35. Udyavar A, Alli R, Nguyen P, Baker L, Geiger TL. 2009 Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity. J. Immunol. 182, 4439–4447. (doi:10.4049/jimmunol.0804377)
36. Louie KA, Weiner LP, Du J, Kochounian HH, Fling SP, Wei W, McMillan M. 2005 Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis. Gene Ther. 12, 1145–1153. (doi:10.1038/sj.gt.3302503)
37. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, Strong R, Theobald M, Greenberg PD. 2009 Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J. Exp. Med. 206, 463–475. (doi:10.1084/jem.20082487)
38. Morgan RA et al. 2013 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151. (doi:10.1097/CJI.0b013e3182829903)
39. Linette GP et al. 2013 Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122, 863–871. (doi:10.1182/blood-2013-03-490565)
40. Cameron BJ et al. 2013 Identification of a titinderived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103. (doi:10.1126/scitranslmed.3006034)
41. Bendle GM et al. 2010 Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565–570. (doi:10.1038/nm.2128)
42. Torikai H et al. 2012 A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697–5705. (doi:10.1182/blood-2012-01-405365)
43. Provasi E et al. 2012 Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807–815. (doi:10.1038/nm.2700)
44. Riddell SR et al. 1996 T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2, 216–223. (doi:10.1038/nm0296-216)
45. Scholler J et al. 2012 Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132R-A153. (doi:10.1126/scitranslmed.3003761)
46. Ho YC et al. 2013 Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551. (doi:10.1016/j.cell.2013.09.020)
47. Hu¨tter G et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–696. (doi:10.1056/NEJMoa0802905)
48. Rossi JJ, June CH, Kohn DB. 2007 Genetic therapies for HIV/AIDS. Nat. Biotechnol. 25, 1444–1454. (doi:10.1038/nbt1367)
49. Levine BL, Bernstein W, Craighead N, Lindsten T, Thompson CB, June CH. 1997 Effects of CD28 costimulation on long term proliferation of CD4 þ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921–5930.
50. Hirano N et al. 2006 Engagement of CD83 ligand induces prolonged expansion of CD8þ T cells and preferential enrichment for antigen specificity. Blood 107, 1528–1536. (doi:10.1182/blood-2005-05-2073)
51. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH. 2007 Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 15, 981–988. (doi:10.1038/mt.sj.6300134)
52. Butler MO, Hirano N. 2014 Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol. Rev. 257, 191–209. (doi:10.1111/imr.12129)
53. Kaneko S et al. 2009 IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006–1015. (doi:10.1182/blood-2008-05-156059)
54. Fowler DH. 2014 Rapamycin-resistant effector T-cell therapy. Immunol. Rev. 257, 210–225. (doi:10.1111/imr.12127)
55. Pearce EL, Pearce EJ. 2013 Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633–643. (doi:10.1016/j.immuni.2013.04.005)
56. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM. 2011 Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol. Ther. 19, 2239–2248. (doi:10.1038/mt.2011.179)
57. Lugli E et al. 2013 Superior T memory stem cell persistence supports long-lived T cell memory. J. Clin. Invest. 123, 594–599. (doi:10.1172/jci66327)
58. Gattinoni L et al. 2011 A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290–1297. (doi:10.1038/nm.2446)
59. Ghosh A, Holland AM, van den Brink MR. 2014 Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol. Rev. 257, 226–236. (doi:10.1111/imr.12142)
60. Zakrzewski JL et al. 2006 Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat. Med. 12, 1039–1047. (doi:10.1038/nm1463)
61. Weng NP. 2006 Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 24, 495–499. (doi:10.1016/j.immuni.2006.05.001)
62. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. 2005 Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046–7052. (doi:10.4049/jimmunol.175.10.7046)
63. Weng NP, Levine BL, June CH, Hodes RJ. 1997 Regulation of telomerase RNA template expression in human T lymphocyte development and activation. J. Immunol. 158, 3215–3220.
64. Weng NP, Palmer LD, Levine BL, Lane HC, June CH, Hodes RJ. 1997 Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol. Rev. 160, 43–54. (doi:10.1111/j.1600-065X.1997.tb01026.x)
65. Giannoni F et al. 2013 Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol. Ther. 21, 1044–1054. (doi:10.1038/mt.2013.8)
66. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. 2013 Generation of tumortargeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928–933. (doi:10.1038/nbt.2678)
67. Gschweng E, De Oliveira S, Kohn DB. 2014 Hematopoietic stem cells for cancer immunotherapy. Immunol. Rev. 257, 237–249. (doi:10.1111/imr.12128)
68. Crompton JG, Sukumar M, Restifo NP. 2014 Uncoupling T-cell expansion from effector differentiation in cellbased immunotherapy. Immunol. Rev. 257, 264–276. (doi:10.1111/imr.12135)
69. Hacein-Bey-Abina S et al. 2008 Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132–3142. (doi:10.1172/JCI35700)
70. Muul LM et al. 2003 Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101, 2563–2569. (doi:10.1182/blood-2002-09-2800)
71. Bushman FD. 2007 Retroviral integration and human gene therapy. J. Clin. Invest. 117, 2083–2086. (doi:10.1172/JCI32949)
72. Newrzela S et al. 2012 T-cell receptor diversity prevents T-cell lymphoma development. Leukemia 26, 2499–2507. (doi:10.1038/leu.2012.142)
73. Marktel S et al. 2003 Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-celldepleted stem cell transplantation. Blood 101, 1290–1298. (doi:10.1182/blood-2002-08-2351)
74. Di Stasi A et al. 2011 Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683. (doi:10.1056/NEJMoa1106152)
75. Zhou X et al. 2014 Long-term outcome and immune reconstitution after haploidentical stem cell transplant in recipients of allodepleted-T-cells expressing the inducible caspase-9 safety transgene. Blood 123, 3896–3905. (doi:10.1182/blood-2014-01-551671)
76. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. 2011 T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73. (doi:10.1126/scitranslmed.3002842)
77. Grupp SA et al. 2013 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518. (doi:10.1056/NEJMoa1215134)
78. Yee C. 2014 The use of endogenous T cells for adoptive transfer. Immunol. Rev. 257, 250–263. (doi:10.1111/imr.12134)